@article {Khera19002162, author = {Rohan Khera and Yongfei Wang and Susannah M. Bernheim and Zhenqiu Lin and Harlan M. Krumholz}, title = {Post-discharge Acute Care and Outcomes in the Era of Readmission Reduction: A National Retrospective Cohort Study of Medicare Beneficiaries in the United States}, elocation-id = {19002162}, year = {2019}, doi = {10.1101/19002162}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background With incentives to reduce readmission rates in the United States, there are concerns that patients who need hospitalization after a recent hospital discharge may be denied access, which would increase their risk of mortality.Objective We determined whether patients with hospitalizations for conditions covered by national readmission programs who received care in emergency department (ED) or observation units but were not hospitalized within 30 days had an increased risk of death. We also evaluated temporal trends in post-discharge acute care utilization in inpatient units, emergency department (ED) and observation units for these patients.Design, Setting, and Participants In this observational study of national Medicare claims data for 2008-2016, we identified patients >=65 years hospitalized with heart failure (HF), acute myocardial infarction (AMI), or pneumonia, conditions included in the HRRP.Main Outcomes and Measures Post-discharge 30-day mortality according to patients{\textquoteright} 30-day acute care utilization. Acute care utilization in inpatient and observation units, and the ED during the 30-day and 31-90-day post-discharge period.Results There were 3,772,924 hospitalizations for HF, 1,570,113 for AMI, and 3,131,162 for pneumonia. The overall post-discharge 30-day mortality was 8.7\% for HF, 7.3\% for AMI, and 8.4\% for pneumonia. Risk-adjusted mortality increased annually by 0.05\% (95\% CI, 0.02\% to 0.08\%) for HF, decreased by 0.06\% (95\% CI, -0.09\% to -0.04\%) for AMI, and did not significantly change for pneumonia. Specifically, mortality increased for HF patients who did not utilize any post-discharge acute care, increasing at a rate of 0.08\% per year (95\% CI, 0.05\% to 0.12\%), exceeding the overall absolute annual increase in post-discharge mortality in heart failure, without an increase in mortality in observation units or the ED. Concurrent with a reduction in 30-day readmission rates, 30-day observation stays and visits to the ED increased across all 3 conditions during and beyond the post-discharge 30-day period. There was no significant change in overall 30-day post-acute care utilization.Conclusions The only condition with an increasing mortality through the study period was HF; the increase preceded the policy and was not present among those received ED or observation unit care without hospitalization. Overall, during this period, there was not a significant change in the overall 30-day post-discharge acute care utilization.What is already known on this topicAmong Medicare beneficiaries hospitalized for heart failure, mortality in the 30-day post-discharge period has been increasing over the past several years. However, the relationship between post-discharge acute care and mortality in the early post-discharge period remains poorly understood.Observation units and the emergency departments (ED) have increasingly been used as avenues for patient care in the United States. However, the utilization of these services in the early post-discharge period for conditions targeted in the Hospital Readmissions Reduction Program (HRRP), and the outcomes of patients in these settings, is required to appropriately evaluate the effects of the program.What this study addsAmong conditions targeted in the HRRP, patients with heart failure, but not those with acute myocardial infarction or pneumonia, experienced increase in post-discharge 30-day mortality. This increase preceded the announcement of the program and was concentrated among individuals who sought no post-discharge acute care, nearly half of whom had been discharged to hospice.Despite increasing utilization of observation units and the ED in the post-discharge period, care in these settings was not associated with increased mortality risk.Competing Interest StatementDr. Krumholz is a recipient of a research grant, through Yale, from Medtronic and Johnson \& Johnson (Janssen) to develop methods of clinical trial data sharing; was a recipient of a research grant, through Yale, from Medtronic and the Food and Drug Administration to develop methods for post-market surveillance of medical devices; was a recipient of a research agreement, through Yale, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion, and collaborates with the National Center for Cardiovascular Diseases in Beijing; received payment from the Arnold \& Porter Law Firm for work related to the Sanofi clopidogrel litigation and from the Ben C. Martin Law Firm for work related to the Cook IVC filter litigation; chairs a cardiac scientific advisory board for UnitedHealth; is a participant/participant representative of the IBM Watson Health Life Sciences Board; is a member of the Advisory Board for Element Science, the Physician Advisory Board for Aetna, and the Advisory Board for Facebook; and is the founder of Hugo, a personal health information platform. Drs. Krumholz, Bernheim, and Lin, and Mr. Wang work under contract with the Centers for Medicare \& Medicaid Services to develop and maintain performance measures that are publicly reported. The other authors report no potential conflicts of interest. The study was conceived and conducted by the authors, and the Centers for Medicare \& Medicaid Services played no role in its design and conduct; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. Funding StatementDr. Khera is supported by the National Center for Advancing Translational Sciences (UL1TR001105) of the National Institutes of Health. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.Not ApplicableAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesThe data are proprietary to the Centers for Medicare and Medicaid Services and can be obtained from them directly. The statistical code is available from the corresponding author.}, URL = {https://www.medrxiv.org/content/early/2019/11/15/19002162}, eprint = {https://www.medrxiv.org/content/early/2019/11/15/19002162.full.pdf}, journal = {medRxiv} }